Another aim of therapeutic inhibition is activation of the c-Met/HGF signalling pathway, which is recognized as a major contributing factor to HNSCC resistance to EGFR, cisplatin, and radiation [25]. This evidence concerns the gene HGF and head and neck squamous cell carcinoma.